OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more
OS Therapies Incorporated (OSTX) - Net Assets
Latest net assets as of September 2025: $4.71 Million USD
Based on the latest financial reports, OS Therapies Incorporated (OSTX) has net assets worth $4.71 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.95 Million) and total liabilities ($4.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.71 Million |
| % of Total Assets | 52.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
OS Therapies Incorporated - Net Assets Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OS Therapies Incorporated (2020–2024)
The table below shows the annual net assets of OS Therapies Incorporated from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $811.49K | +103.38% |
| 2023-12-31 | $-24.02 Million | -36.79% |
| 2022-12-31 | $-17.56 Million | -53.32% |
| 2021-12-31 | $-11.45 Million | +99.82% |
| 2020-12-31 | $-6.33 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to OS Therapies Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 629524765000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.87K | 2.57% |
| Other Components | $41.19 Million | 5076.48% |
| Total Equity | $811.49K | 100.00% |
OS Therapies Incorporated Competitors by Market Cap
The table below lists competitors of OS Therapies Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MacroWell OMG Digital Entertainment Co Ltd
TWO:3687
|
$41.14 Million |
|
Widepoint C
NYSE MKT:WYY
|
$41.16 Million |
|
Toubani Resources Ltd
AU:TRE
|
$41.17 Million |
|
Hvidbjerg Bank
CO:HVID
|
$41.17 Million |
|
XXL ASA
OL:XXL
|
$41.13 Million |
|
BBGI PCL
BK:BBGI
|
$41.12 Million |
|
Progress-Werk Oberkirch AG
XETRA:PWO
|
$41.10 Million |
|
Drone Volt SA
PA:ALDRV
|
$41.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OS Therapies Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -24,016,215 to 811,487, a change of 24,827,702.
- Net loss of 8,882,938 reduced equity.
- Dividend payments of 31,250,000 reduced retained earnings.
- New share issuances of 11,275,840 increased equity.
- Other factors increased equity by 53,684,800.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.88 Million | -1094.65% |
| Dividends Paid | $31.25 Million | -3850.96% |
| Share Issuances | $11.28 Million | +1389.53% |
| Other Changes | $53.68 Million | +6615.61% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares OS Therapies Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 39.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-751.22 | $1.53 | x |
| 2021-12-31 | $-0.50 | $1.53 | x |
| 2022-12-31 | $-0.76 | $1.53 | x |
| 2023-12-31 | $-1.20 | $1.53 | x |
| 2024-12-31 | $0.04 | $1.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OS Therapies Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1094.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.83x
- Recent ROE (-1094.65%) is below the historical average (-218.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $632.68 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.28 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.50 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.39 Million |
| 2024 | -1094.65% | 0.00% | 0.00x | 6.83x | $-8.96 Million |
Industry Comparison
This section compares OS Therapies Incorporated's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OS Therapies Incorporated (OSTX) | $4.71 Million | 0.00% | 0.90x | $41.13 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |